SCHEMBL5090977

SCHEMBL5090977

Cn1nc(-c2ccc(C(=O)N3CCN(S(=O)(=O)c4cc5cc(Cl)ccc5[nH]4)CC3)cc2)ccc1=O

nearest known ligand 0.68

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
F10 P00742 18/20 0.68
KLK1 P06870 1/20 0.68
HRH3 Q9Y5N1 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5088843 0.89 F10 (0.67) F10KLK1
SCHEMBL5092554 0.89 F10 (0.62) F10KLK1
SCHEMBL5099270 0.88 F10 (0.62) F10KLK1
SCHEMBL5088851 0.88 F10 (0.61) F10KLK1
SCHEMBL5091013 0.88 F10 (0.61) F10KLK1
SCHEMBL5090966 0.88 F10 (0.61) F10KLK1
SCHEMBL5090992 0.88 F10 (0.61) F10KLK1
SCHEMBL5088795 0.88 F10 (0.63) F10KLK1
SCHEMBL5088821 0.86 F10 (0.58) F10KLK1
SCHEMBL5088849 0.85 F10 (0.58) F10KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135441-A1 New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one ASTRAZENECA AB (SE) 2007-06-14 US claimed
CN-1905883-A Novel derivatives of 6- { 4- [ 4- (1H-indole-2-sulfonyl) -piperazine-1-carbonyl-phenyl ] } pyridazin-3-one ASTRAZENECA AB (SE) 2007-01-31 CN claimed
US-7419979-B2 Derivatives of 6-{4-[4-(1H-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one ASTRAZENECA AB (SE) 2008-09-02 US disclosed
US-20070135441-A1 New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one ASTRAZENECA AB (SE) 2007-06-14 US disclosed
CN-1905883-A Novel derivatives of 6- { 4- [ 4- (1H-indole-2-sulfonyl) -piperazine-1-carbonyl-phenyl ] } pyridazin-3-one ASTRAZENECA AB (SE) 2007-01-31 CN disclosed
EP-1706120-A1 NEW DERIVATIVES OF 6- 4 4 - 1 H - INDOLE-2-SULPHONYL)-PIPERA ZIN-1-CARBONYL-PHENYL PYRADIZIN-3-ONE AstraZeneca AB (SE) 2006-10-04 EP disclosed
WO-2005065688-A1 NEW DERIVATIVES OF 6-4{4-[1H-INDOLE-2-SULPHONYL)-PIPERAZIN-1-CARBONYL-PHENYL]}PYRADIZIN-3-ONE ASTRAZENECA AB (SE) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135441-A1 New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one HTR7, TRPC7, HRH4 F10 803/4885KLK1 3405/4885HRH3 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.